Published in Blood Weekly, February 5th, 2004
Thios has renamed the rPSGL-Ig compound TS1.
"This agreement provides an important strategic opportunity for Thios to move quickly into clinical trials with a sulfated therapeutic. TS1 has an outstanding safety profile with over 500 patients treated safely, complements our existing pipeline of potential products and enhances our leadership position in the sulfation field," said Bruce A. Hironaka, president and chief...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.